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Abstract
Background: Etoposide is currently one of the most commonly used antitumor drugs. The
mechanisms of action proposed for its antitumor activity are based mainly on its interaction with
topoisomerase II. Etoposide effects in transformed cells have been described previously. The aim
of the present study was to evaluate the genotoxic effects of this drug in non-transformed whole
blood cells, such as occurs as collateral damage induced by some chemotherapies.
Methods:  To determine etoposide genotoxicity, we employed Comet assay in two alkaline
versions. To evaluate single strand breaks and delay repair sites we use pH 12.3 conditions and pH
>13 to evidence alkali labile sites. With the purpose to quantified apurinic or apyrimidine (AP) sites
we employed a specific restriction enzyme. Etoposide effects were determined on whole blood
cells cultured in absence or presence of phytohemagglutinin (PHA) treated during 2 and 24 hours
of cultured.
Results: Alkaline (pH > 13) single cell gel electrophoresis (SCGE) assay experiments revealed
etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and
non-stimulated blood cells. When the assay was performed at a less alkaline pH, 12.3, we observed
DNA damage in PHA-stimulated blood cells consistent with the existence of alkali labile sites
(ALSs). In an effort to elucidate the molecular events underlying this result, we applied exonuclease
III (Exo III) in conjunction with a SCGE assay, enabling detection of DNA-AP sites along the
genome. More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE
assay only in the non-stimulated blood cells treated with etoposide.
Conclusion: Our results indicate that etoposide induces DNA damage specifically at DNA-AP
sites in quiescent blood cells. This effect could be involved in the development of secondary
malignancies associated with etoposide chemotherapy.
Background
In the last decade, etoposide (also known as VP-16213)
has been one of the most commonly used agents for treat-
ing a number of malignancies. Etoposide is a semi-syn-
thetic derivative of epipodophyllotoxin derived from the
plant Podophyllum peltatum [1-3]. Its primary intracellular
target, topoisomerase II, alters DNA topology by passing
an intact double helix through a transient double
stranded break that it generates in a separate nucleic acid
segment [4-6].
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Topoisomerase II is required to resolve knots and tangles
in the genetic material that are produced by physiological
processes such as DNA recombination and replication [7-
12]. In the absence of topoisomerase II, cells are unable to
segregate daughter chromosomes and die of mitotic fail-
ure [13].
In contrast to most drugs that target specific enzymes,
etoposide and other topoisomerase II-targeting anticancer
agents act in a subtle manner. Rather than blocking the
activity of this essential enzyme, etoposide kills cells by
increasing the concentration of topoisomerase II-DNA
cleavage complexes [7,12,14-16]. This action converts
topoisomerase II into a potent cellular toxin that frag-
ments the genome. Consequently, etoposide has been
deemed a topoisomerase II poison, distinct from drugs
that inhibit the overall catalytic activity of an enzyme
[7,12,14-18]. It has been known for more than a decade
that etoposide stabilizes topoisomerase II-associated DNA
breaks, thereby abolishing the ability of the enzyme to
ligate cleaved nucleic acid molecules [7,12,16,19-21].
Specifically when etoposide interacts with topoisomerase
IIα, it traps the enzyme in a covalently bound form with
its DNA substrate [5,22].
The topoisomeriase IIα-DNA complex is stabilized with
the etoposide molecule by hydrogen bonds with the
nucleic acid bases, and this stabilized complex thus pre-
vents re-ligation of DNA by topoisomerase IIα [23,24].
Both double-and single-strand breaks (SSBs) in DNA can
be produced by etoposide.
The production of free radicals during etoposide metabo-
lism has also been observed [25-27]. An orthoquinone
metabolite of etoposide can be transformed into a hydro-
quinone [21]. When oxidized, hydroquinones give rise to
hydroxyl radicals, which may ultimately contribute to
etoposide-associated SSBs in DNA [28]. Although, the
etoposide mechanism of action is well described in trans-
formed cells, is important to know the effects generated in
non-transformed whole blood cells as they are also
exposed to the antineoplastic drug.
The Single Cell Gel Electrophoresis (SCGE) assay, also
known as the comet assay, has been proposed as a sensi-
tive, reliable and rapid method for detecting DNA SSBs,
alkali labile sites (ALSs), and delayed repair sites (DRSs)
in eukaryotic cells under extremely alkaline conditions
(pH > 13) [29,30]. Meanwhile, the SCGE assay reveals
only SSBs and DRSs under less extreme alkali conditions
(i.e. pH 12.3). Thus by comparing the SCGE results
obtained at pH 12.3 to those obtained pH >13, it is possi-
ble to discriminate the accumulation of apurinic and apy-
rimidinic sites (AP sites), which produce ALSs, from other
forms of DNA damage.
In this study, we used the alkaline SCGE assay at pH 12.3
and pH >13 in non-stimulated and PHA-stimulated
human blood cells to assess the genotoxicity associated
with etoposide-induced oxidative stress in non-trans-
formed cells. We performed follow-up assays with exonu-
clease III enzyme (Exo III) to detect DNA-AP sites within
the genome [31]. The effect of co-treatment with an anti-
oxidant, on etoposide genotoxicity was also examined. If
etoposide treatment generates the production of reactive
oxygen species, principally phenoxyl radicals, in non-
stimulated whole blood cells, then exposure to an antioxi-
dant should reduce the extent of DNA damage induced.
Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA),
ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sul-
foxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-
1640 medium, and etoposide were obtained from Sigma
Chemical Co. (St. Louis, MO), NaOH and NaCl were
obtained from Merck (Mexico) and Baxter (Mexico),
respectively. Exo III was obtained from Amersham Life
Science (Piscataway, NJ, USA). Ascorbic acid (AA), also
known as vitamin C, was obtained from ICN (Mexico).
Human blood cells and treatments
The protocol was approved by the Ethics committee of
Instituto de Investigaciones Biomédicas at Universidad
Nacional Autónoma de México. Whole blood samples
were obtained by vein punction from normal healthy vol-
unteers, who were non-smokers and not taking any med-
ications. PHA-stimulated and non-stimulated whole
blood cells were treated for 2 or 24 h with different etopo-
side concentrations (0, 2.07, 20.7 and 207 μM), in the
presence of RPMI-1640 culture medium and maintained
at 37°C under 5% CO2 conditions.
The etoposide concentrations were determined by assum-
ing a body surface area of 1.63 m2 for the volunteers and
calculating a dose equivalent to that used clinically for
hematological malignancies. The calculated equivalent of
the clinical dose was taken as the highest concentration
applied in our study.
PHA-stimulated whole blood was first incubated for 6 h at
37°C under 5% CO2 conditions in 1 ml of RPMI-1640
culture medium with 71 μl of PHA, and then treated with
etoposide as described above. To test the attenuation of
etoposide AP-site generation in non-stimulated blood
cells, the cultures were treated at the same time with AA
(200 μM).
Viability
The dual cell-stain assay described by Hartman and Speit
[32] was employed to determine the viability of the PHA-BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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stimulated and the non stimulated whole blood cells after
etoposide treatments. The analysis was performed with a
fluorescence microscope (Olympus BX60); 4 fields and at
least 400 cells per slide were scored. The results were
expressed as percentage of cells alive relative to controls.
Single cell gel electrophoresis
The alkaline comet assay was performed essentially as
described previously [33]. Briefly, after the experimental
treatment was applied, 20-μl samples of whole blood,
both PHA-stimulated and non-stimulated, were dissolved
in 0.5% LMPA, spread onto microscope slides precoated
with 0.5% agarose, and covered with an additional 0.5%
LMPA layer. The cells were then lysed in a high salt and
detergent solution (2.5 M NaCl, 10 mM EDTA, 10 mM
Tris pH 10, with fresh 10% DMSO and 1%Triton x-100),
for at least 1 h at 4°C. Subsequently, the cells were placed
in a horizontal electrophoresis chamber and exposed to
an alkaline solution (300 mM NaOH, 1 mM Na2EDTA,
pH >13) for 20 min to allow the DNA to unwind. For
DNA electrophoresis, a 25-V electric current (300 mA, 0.8
V/cm) was applied for 20 min. All technical steps were
conducted under very dim indirect light. After electro-
phoresis, the slides were gently removed and the alkaline
pH was neutralized by application of 0.4 M Tris, pH 7.5.
The slides were dehydrated in two steps with absolute eth-
anol for 5 min each. Ethidium bromide (75 μl of a 20 μg/
ml solution) was added to each slide and a coverglass was
placed on the gel.
We performed the comet assay at pH 12.3 as described in
our previous report [33]. The comet assay was also used in
combination with Exo III as described by Gedik et al. [34].
Briefly, cells were centrifuged at 200 × g for 3 min at 4°C,
dispersed in 75 μl 1% low melting point agarose at 37°C,
placed on a microscope slide an processed for the comet
assay. For each sample, we divided the gel in two parts, the
upper part of the gel was incubated with ExoIII and buffer
and lower part with buffer alone. The parts were separated
by a coverglass.
The measures of AP sites were obtained by subtraction of
the mean comet assay score with enzyme buffer alone
from that with ExoIII. DNA migration was analyzed on an
Olympus BMX60 microscope with epifluorescence equip-
ment (with a 515-560-nm excitation filter and a 590-nm
barrier filter). DNA migration measurements (tail image
length, in microns) were made with a scaled ocular. To
identify the tail, the head of the comet was defined as the
most brilliant circular region in the image. One hundred
cells were scored for each treatment condition. All experi-
ments were conducted in triplicate and scored in a double
blind manner.
Statistical analysis
All statistical analyses were performed with STATISTICA
software version 5 from STAT Soft Inc. USA (1996). The
Mann-Whitney U test was used to determine DNA dam-
age statistical differences between control cells and those
treated with etoposide. Student's t test was used to com-
pare cell viability, and Exo III recognition sites between
control and etoposide-treated cells. For the evaluation of
ALS, we used the Shapiro-Wilk "W" test which is used to
probe normality [35]. We compared each treatment with
its particular control (2 h non-stimulated, 2 h stimulated,
24 h non-stimulated and 24 h stimulated) and with each
etoposide concentration (0.0, 2.07, 20.7, 207.0). The
results reported show that W test was not significant in all
case (2 h non-stimulated, W = 0.867, P = 0.06148; 24 h
non-stimulated, W = 0.9093, P = 0.20902); 2 h stimu-
lated, W = 0.91198, P = 0.22618; 24 h stimulated, W =
0.93917, P = 0.48735, then the hypothesis that the respec-
tive distribution is normal was accepted. We performed a
one way ANOVA test in order to detect if there was an
effect of the etoposide concentration (0.0, 2.07, 20.7,
207.0) on the formation of akali-labile sites (ALS) in stim-
ulated and non-stimulated cells at 2 h and 24 h.
Thereafter, a multiple comparison test (Tukey) was used
to determine the significant differences between group
means, particularly we analyzed if the control differed sig-
nificantly with each etoposide concentration [35]. The
relationship between ALS index and net enzyme recogni-
tion sites was analyzed by Pearson's correlation.
Results
Viability
Our observations of the cells following the dual cell-stain
method for PHA-stimulated and non-stimulated whole
blood cells revealed that cell viability was high after
etoposide treatment for 2 h and 24 h. As shown in table 1,
we observed cell viability rates that exceeded 70%.
Single cell gel electrophoresis
SCGE at pH >13, which reveals SSBs, DRSs and ALSs,
revealed a dose-dependent effect of etoposide treatment
(2.07, 20.7 and 207 μM) on cells treated for 2 h and 24 h
(Figure 1A, B respectively). We observed an increase in
DNA-damage in all etoposide treatments showing the
highest effect at 207 μM with respect to the control. How-
ever, SCGE assay performed at pH 12.3, which detect SSBs
and DRSs, but not ALSs, showed genotoxic effects in the
PHA-stimulated whole blood cells only at both treatment
durations (Figure 2). These results demonstrate oxidative
DNA damage generated by etoposide in non-stimulated
blood cells, among others sources of ALS generation [35].BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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Alkali labile site (ALS) index
The ALS index was determined as the difference between
the DNA damage detected at pH 12.3 and the damage esti-
mated at pH>13 by the SCGE assay. All data were normal-
ized with respect to the controls. As shown in Figure 3,
non-stimulated whole blood cells had higher ALS index
values than PHA-stimulated cells treated with etoposide.
Control cells differed from etoposide-treated cells in all
conditions except in PHA-stimulated cells treated for 24 h.
The ANOVA analysis showed that there was a significant
effect of etoposide concentration (0.0, 2.07, 20.7, 207.0)
on the formation of ALS in all treatments: 2 h non-stimu-
lated (F3 = 442.97, P < 0.0000), 24 h non-stimulated (F3 =
246.66, P < 0.0000) 2 h stimulated (F3 = 50.35,> P <
0000) 24 h stimulated (F3 = 9.52, P < 0.01).; these find-
ings were consistent with the SCGE data (Figure 3).
DNA AP-sites detection
To test the hypothesis that ALSs generated by etoposide-
oxidative stress could develop into DNA-AP sites, we used
the enzyme Exo III, which recognizes this kind of DNA
lesions. This analysis was performed in non-stimulated
whole blood cells treated for 2 h with etoposide, a condi-
tion which produces a high rate of ALS induction, and the
results were compared with the data from the PHA-stimu-
lated whole blood cells exposed to etoposide for 24 h. As
shown in figure 4, we observed a relationship between
percentage of AP-sites and etoposide concentration in
non-stimulated whole blood cells relative to PHA-stimu-
lated blood cells subjected to the longer treatment.
Because the presence of ALSs in non-stimulated whole
blood cells was inferred indirectly by comparing the SCGE
assays under the two pH conditions, it was important to
test whether these putative ALSs involved AP-sites. There-
fore we examined whether there was an association
between the ALS index data and the DNA AP-sites data, as
revealed by the use of Exo III. Indeed, we found a signifi-
cant positive correlation (r = 0.90; p < 0.01) between ALS
index value and the percent of DNA-AP sites detected by
Exo-III (Figure 5).
If etoposide treatment induces ROS, principally phenoxyl
radicals in non-stimulated whole blood cells, then an
antioxidant exposure should reduce the DNA damage
induced by etoposide. As shown in figure 6, we found that
a 2-h treatment course with the antioxidant AA (200 μM)
concurrent with the 2-h etoposide treatment reduced the
DNA damage induced by etoposide in non-stimulated
whole blood cells. This finding indicates that AA provided
some level of protection for the non-stimulated blood cell
DNA in the oxidative micro-environment generated by
the etoposide.
Discussion
Etoposide affects chromatin function by directly and
physically interfering with topoisomerase IIα enzyme
activity. Topoisomerase IIα is considered to be an impor-
tant player in the maintenance of the DNA double helix,
due to its capacity to regulate conformational changes in
DNA, in normal processes such as replication, transcrip-
tion or condensation and segregation of chromosomes [4-
6].
Topoisomerase IIα activity fluctuates with the cell cycle;
its levels elevate as the cells progress through the cycle
toward mitosis [36-39]. Thus as structural maintenance of
DNA is most challenged during DNA replication, it is
expected that cycling cells would be the most susceptible
to damage in the presence of etoposide. Because non-
stimulated cells are not cycling, they have relatively low
Topoisomerase II activity compared to PHA-stimulated
whole blood cells, and thus would be expected to be rela-
tively insensitive to DNA-damaging effects of etoposide.
The present findings of etoposide-induced DNA damage
in non-stimulated cells differ from the findings of Olive
and Banath [40] which indicated an absence of DNA dam-
Table 1: Viability of non-stimulated and PHA-stimulated blood cells treated with etoposide as determined by dual-cell stain method.
Etoposide 2 h treatment non-stimulated blood cells 2 h treatment PHA-stimulated blood cells
0 μM 100 ± 5.5 100 ± 5.6
2.07 μM 95.5 ± 8.5 88.6 ± 3.9
20.7 μM 99.2 ± 2.2 83.2 ± 8.2
207 μM 91.1 ± 8.2 75.6 ± 7.6
Etoposide 24 h treatment non-stimulated blood cells 24 h treatment PHA-stimulated blood cells
0 μM 100 ± 2.3 100 ± 3.9
2.07 μM 100 ± 3.7 96.7 ± 3.4
20.7 μM 100 ± 8.0 96.7 ± 3.4
207 μM 93.8 ± 8.2 81.4 ± 9.9
Viability % ± SD. Each cell represents the average of three independent experiments.BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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age induction by etoposide in non-cycling cells. This dis-
crepancy is most likely due to inherent differences
between the cells used in the experiments. Olive and
Banath used colon carcinoma cells (WiDr), while we used
human lymphocytes from healthy donors. Lymphocytes,
such as those used here, are normally arrested in the G0
phase and non-transformed.
To asses the molecular processes involved in the etopo-
side treatment-induced breaks, we compared the non-
stimulated whole blood cells genotoxicity data generated
by the SCGE assay under both highly basic (= 12.3) and
extremely basic (> 13) pH conditions and thus generated
the ALS index values (see results section). This compari-
son enables the presence of ALSs to be deduced indirectly
because the oxidative response capable of generating apu-
rinic or apyrimidic sites (AP sites) is pH-dependent
[41,42]. The ALS index data indicated that ALSs, which
can be generated by an oxidative stress [6,33], constituted
the primary form of DNA damage induced by etoposide
in whole blood cells.
To asses whether oxidative stress was responsible for the
DNA damage observed in the etoposide-treated non-stim-
DNA damage in non-stimulated and PHA-stimulated blood  cells caused by 2-h and 24-h etoposide treatment at the indi- cated doses detected by Comet Assay at pH > 13 Figure 1
DNA damage in non-stimulated and PHA-stimulated 
blood cells caused by 2-h and 24-h etoposide treat-
ment at the indicated doses detected by Comet 
Assay at pH > 13. A) 2-h treatment; B) 24-h treatment. 
Each bar represents the mean value of three independent 
experiments. Data were analyzed using the Mann-Whitney U 
test. (*= p < 0.05, ** = p < 0.01, *** = p < 0.001 vs. control).
DNA damage in non-stimulated and PHA-stimulated blood  cells caused by 2-h and 24-h etoposide treatment at the indi- cated doses detected by Comet Assay at pH = 12.3 Figure 2
DNA damage in non-stimulated and PHA-stimulated 
blood cells caused by 2-h and 24-h etoposide treat-
ment at the indicated doses detected by Comet 
Assay at pH = 12.3. A) 2-h treatment; B) 24-h treatment. 
Each bar represents the mean value of three independent 
experiments. Data were analyzed using the Mann-Whitney U 
test. (*= p < 0.05, *** = p < 0.001 vs. control).BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and PHA stimulated  blood cells Figure 3
Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and 
PHA stimulated blood cells. Data were analyzed using one way Anova test. (* p < 0.05 vs. control; *** p < 0.001 vs. con-
trol).
Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA- stimulated blood cells treated 24-h with etoposide Figure 4
Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 
2-h and PHA-stimulated blood cells treated 24-h with etoposide. Data were analyzed using one way Anova test. (**p 
< 0.01 vs. control; ***p < 0.001 vs. control).BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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DNA damage induced by etoposide (0, 2.07, 20.7 or 207 μM) in non-stimulated blood cells treated for 2-h (open bars) and  DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars) Figure 6
DNA damage induced by etoposide (0, 2.07, 20.7 or 207 μM) in non-stimulated blood cells treated for 2-h (open 
bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide 
(solid bars). Every bar represents the mean value of three independent experiments. Data were analyzed using the Mann-
Whitney U test. (*= p < 0.05; **= p < 0.005 vs. control; ***= p < 0.001 vs. corresponding no AA condition).
Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated  blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide Figure 5
Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in 
non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398
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ulated cells, we used the SCGE assay in combination with
Exo III, an enzyme that recognizes AP sites in DNA. The
results corroborated the presence of DNA-AP sites in the
genomes of the non-stimulated cells treated with etopo-
side. Moreover, when non-stimulated cells were exposed
to etoposide in the presence of the antioxidant AA, less
DNA damage was observed. Thus the ability of the anti-
oxidant to protect the DNA suggests that phenoxyl radi-
cals are the major radicals involved in the oxidative DNA-
damage induced by etoposide, especially in non-stimu-
lated cells [[27,43], and [44]].
Interestingly, our results suggest that the molecular events
by which DNA breaks are generated in PHA-stimulated
and non-stimulated cells are quite different. The damage
observed in the PHA-stimulated whole blood cells could
be explained by the classical events ascribed to topoi-
somerase II poisons [12].
These have two principal components: DNA strand breaks
due to the inhibition of topoisomerase II by etoposide
and etoposide-quinone free radical effects [25,45]. Tor-
nov and colleagues [46] observed DNA damage in leuko-
cytes evidenced by SCGE assay at pH 13, suggesting that
etoposide might cause oxidative damage in leukocytes by
a mechanism involving inhibition of the enzyme topoi-
somerase IIβ. Although the exact function of this enzyme
has not been resolved, it is known that its concentration is
generally independent of cell cycle and cell growth
[[12,37,39], and [46]]. In addition, topoisomerase IIβ is
expressed at a higher level than topoisomerase IIα in
human peripheral blood cells [47]. If the AP site damage
observed in the present study was dependent upon an
interaction with this enzyme, we should have also
observed this kind of damage in PHA-stimulated whole
blood cells. However our findings were not consistent
with this prediction.
It is our view that the induction of damage at DNA-AP
sites observed in non-stimulated whole blood cells herein
was due to interaction of the drug metabolites with cellu-
lar targets beyond topoisomerase IIβ (which was not
present at high levels), such as DNA and/or proteins.
Interaction of the drug metabolites with these alternative
targets can cause DNA damage by the generation of free
radicals [28]. Another possible explanation could be that
DNA repair status in non-stimulated whole blood cells are
less active than stimulated whole blood cells to remove
this kind of DNA damage [48]. Moreover, the reduced
DNA damage in the presence of the antioxidant AA sug-
gests that etoposide-hydroquinone phenoxyl radical is the
responsible mediator of these effects [27,49].
Conclusion
In summary, our data show that etoposide can produce
differential forms of DNA damage in PHA-stimulated and
non-stimulated blood cells. These results could have
important implications for elucidating the mechanisms
associated with the development of secondary malignan-
cies (principally acute mielocitic leukemia) that are asso-
ciated with the use of etoposide as an antineoplastic drug
[50].
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